David Endesfelder1, Michael Hagen1, Christiane Winkler2,3,4,5, Florian Haupt2,3,4, Stephanie Zillmer2,3,4, Annette Knopff2,3, Ezio Bonifacio5,6,7,8, Anette-G Ziegler2,3,4,5, Wolfgang Zu Castell9,10, Peter Achenbach11,12,13,14. 1. Scientific Computing Research Unit, Helmholtz Zentrum München, Ingolstaedter Landstrasse 1, 85764, Neuherberg, Germany. 2. Institute of Diabetes Research, Helmholtz Zentrum München, Ingolstaedter Landstrasse 1, 85764, Neuherberg, Germany. 3. Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München, München, Germany. 4. German Center for Diabetes Research (DZD), Neuherberg, Germany. 5. Forschergruppe Diabetes e.V., Neuherberg, Germany. 6. DFG Research Center for Regenerative Therapies Dresden, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany. 7. Paul Langerhans Institute Dresden, German Center for Diabetes Research (DZD), Technische Universität Dresden, Dresden, Germany. 8. Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany. 9. Scientific Computing Research Unit, Helmholtz Zentrum München, Ingolstaedter Landstrasse 1, 85764, Neuherberg, Germany. castell@helmholtz-muenchen.de. 10. Department of Mathematics, Technische Universität München, München, Germany. castell@helmholtz-muenchen.de. 11. Institute of Diabetes Research, Helmholtz Zentrum München, Ingolstaedter Landstrasse 1, 85764, Neuherberg, Germany. peter.achenbach@helmholtz-muenchen.de. 12. Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München, München, Germany. peter.achenbach@helmholtz-muenchen.de. 13. German Center for Diabetes Research (DZD), Neuherberg, Germany. peter.achenbach@helmholtz-muenchen.de. 14. Forschergruppe Diabetes e.V., Neuherberg, Germany. peter.achenbach@helmholtz-muenchen.de.
Abstract
AIMS/HYPOTHESIS: Progression to type 1 diabetes in children and adolescents is not uniform. Based on individual genetic background and environment, islet autoimmunity may develop at variable age, exhibit different autoantibody profiles and progress to clinical diabetes at variable rates. Here, we aimed to quantify the qualitative dynamics of sequential islet autoantibody profiles in order to identify longitudinal patterns that stratify progression rates to type 1 diabetes in multiple-autoantibody-positive children. METHODS: Qualitative changes in antibody status on follow-up and progression rate to diabetes were analysed in 88 children followed from birth in the prospective BABYDIAB study who developed multiple autoantibodies against insulin (IAA), GAD (GADA), insulinoma-associated antigen-2 (IA-2A) and/or zinc transporter 8 (ZnT8A). An algorithm was developed to define similarities in sequential autoantibody profiles and hierarchical clustering was performed to group children with similar profiles. RESULTS: We defined nine clusters that distinguished children with respect to their sequential profiles of IAA, GADA, IA-2A and ZnT8A. Progression from first autoantibody appearance to clinical diabetes between clusters ranged from 6% (95% CI [0, 16.4]) to 73% (28.4, 89.6) within 5 years. Delayed progression was observed in children who were positive for only two autoantibodies, and for a cluster of 12 children who developed three or four autoantibodies but were IAA-negative in their last samples, nine of whom lost IAA positivity during follow-up. Among all children who first seroconverted to IAA positivity and developed at least two other autoantibodies (n = 57), the 10 year risk of diabetes was 23% (0, 42.9) in those who became IAA-negative during follow-up compared with 76% (58.7, 85.6) in those who remained IAA-positive (p = 0.004). CONCLUSIONS/ INTERPRETATION: The novel clustering approach provides a tool for stratification of islet autoantibody-positive individuals that has prognostic relevance, and new opportunities in elucidating disease mechanisms. Our data suggest that losing IAA reactivity is associated with delayed progression to type 1 diabetes in multiple-islet-autoantibody-positive children.
AIMS/HYPOTHESIS: Progression to type 1 diabetes in children and adolescents is not uniform. Based on individual genetic background and environment, islet autoimmunity may develop at variable age, exhibit different autoantibody profiles and progress to clinical diabetes at variable rates. Here, we aimed to quantify the qualitative dynamics of sequential islet autoantibody profiles in order to identify longitudinal patterns that stratify progression rates to type 1 diabetes in multiple-autoantibody-positive children. METHODS: Qualitative changes in antibody status on follow-up and progression rate to diabetes were analysed in 88 children followed from birth in the prospective BABYDIAB study who developed multiple autoantibodies against insulin (IAA), GAD (GADA), insulinoma-associated antigen-2 (IA-2A) and/or zinc transporter 8 (ZnT8A). An algorithm was developed to define similarities in sequential autoantibody profiles and hierarchical clustering was performed to group children with similar profiles. RESULTS: We defined nine clusters that distinguished children with respect to their sequential profiles of IAA, GADA, IA-2A and ZnT8A. Progression from first autoantibody appearance to clinical diabetes between clusters ranged from 6% (95% CI [0, 16.4]) to 73% (28.4, 89.6) within 5 years. Delayed progression was observed in children who were positive for only two autoantibodies, and for a cluster of 12 children who developed three or four autoantibodies but were IAA-negative in their last samples, nine of whom lost IAA positivity during follow-up. Among all children who first seroconverted to IAA positivity and developed at least two other autoantibodies (n = 57), the 10 year risk of diabetes was 23% (0, 42.9) in those who became IAA-negative during follow-up compared with 76% (58.7, 85.6) in those who remained IAA-positive (p = 0.004). CONCLUSIONS/ INTERPRETATION: The novel clustering approach provides a tool for stratification of islet autoantibody-positive individuals that has prognostic relevance, and new opportunities in elucidating disease mechanisms. Our data suggest that losing IAA reactivity is associated with delayed progression to type 1 diabetes in multiple-islet-autoantibody-positive children.
Entities:
Keywords:
Clustering; Islet autoantibody; Longitudinal; Profiles; Progression; Type 1 diabetes
Authors: I Truyen; P De Pauw; P N Jørgensen; C Van Schravendijk; O Ubani; K Decochez; E Vandemeulebroucke; I Weets; R Mao; D G Pipeleers; F K Gorus Journal: Diabetologia Date: 2005-10-07 Impact factor: 10.122
Authors: P Achenbach; V Lampasona; U Landherr; K Koczwara; S Krause; H Grallert; C Winkler; M Pflüger; T Illig; E Bonifacio; A G Ziegler Journal: Diabetologia Date: 2009-07-10 Impact factor: 10.122
Authors: Andrea K Steck; Fran Dong; Randall Wong; Alexandra Fouts; Edwin Liu; Jihane Romanos; Cisca Wijmenga; Jill M Norris; Marian J Rewers Journal: Pediatr Diabetes Date: 2013-11-08 Impact factor: 4.866
Authors: Sefina Arif; Pia Leete; Vy Nguyen; Katherine Marks; Nurhanani Mohamed Nor; Megan Estorninho; Deborah Kronenberg-Versteeg; Polly J Bingley; John A Todd; Catherine Guy; David B Dunger; Jake Powrie; Abby Willcox; Alan K Foulis; Sarah J Richardson; Emanuele de Rinaldis; Noel G Morgan; Anna Lorenc; Mark Peakman Journal: Diabetes Date: 2014-06-17 Impact factor: 9.461
Authors: Giulia Frazzei; Ronald F van Vollenhoven; Brigit A de Jong; Sarah E Siegelaar; Dirkjan van Schaardenburg Journal: Front Immunol Date: 2022-06-30 Impact factor: 8.786
Authors: Melanie R Shapiro; Clive H Wasserfall; Sean M McGrail; Amanda L Posgai; Rhonda Bacher; Andrew Muir; Michael J Haller; Desmond A Schatz; Johnna D Wesley; Matthias von Herrath; William A Hagopian; Cate Speake; Mark A Atkinson; Todd M Brusko Journal: Diabetes Date: 2019-12-11 Impact factor: 9.461
Authors: Bum Chul Kwon; Peter Achenbach; Jessica L Dunne; William Hagopian; Markus Lundgren; Kenney Ng; Riitta Veijola; Brigitte I Frohnert; Vibha Anand Journal: AMIA Annu Symp Proc Date: 2021-01-25
Authors: Michelle So; Colin O'Rourke; Alyssa Ylescupidez; Henry T Bahnson; Andrea K Steck; John M Wentworth; Brittany S Bruggeman; Sandra Lord; Carla J Greenbaum; Cate Speake Journal: Diabetologia Date: 2022-01-18 Impact factor: 10.122
Authors: Anna E Long; Isabel V Wilson; Dorothy J Becker; Ingrid M Libman; Vincent C Arena; F Susan Wong; Andrea K Steck; Marian J Rewers; Liping Yu; Peter Achenbach; Rosaura Casas; Johnny Ludvigsson; Alistair J K Williams; Kathleen M Gillespie Journal: Diabetologia Date: 2018-03-12 Impact factor: 10.122
Authors: David Endesfelder; Wolfgang Zu Castell; Ezio Bonifacio; Marian Rewers; William A Hagopian; Jin-Xiong She; Åke Lernmark; Jorma Toppari; Kendra Vehik; Alistair J K Williams; Liping Yu; Beena Akolkar; Jeffrey P Krischer; Anette-G Ziegler; Peter Achenbach Journal: Diabetes Date: 2018-10-10 Impact factor: 9.337